Andrew Regan - Net Worth and Insider Trading

Andrew Regan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Andrew Regan owns 1 companies in total, including Conduit Pharmaceuticals Inc (CDT) .

Click here to see the complete history of Andrew Regan’s form 4 insider trades.

Insider Ownership Summary of Andrew Regan

Ticker Comapny Transaction Date Type of Owner
CDT Conduit Pharmaceuticals Inc 2023-09-22 director & 10 percent owner

Andrew Regan Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Andrew Regan Ownership Network

Ownership Network List of Andrew Regan

No Data

Ownership Network Relation of Andrew Regan


Andrew Regan Owned Company Details

What does Conduit Pharmaceuticals Inc do?

Who are the key executives at Conduit Pharmaceuticals Inc?

Andrew Regan is the director & 10 percent owner of Conduit Pharmaceuticals Inc. Other key executives at Conduit Pharmaceuticals Inc include 10 percent owner & other: See Responses Corvus Capital Ltd. , 10 percent owner & other: See Responses Algo Holdings, Inc. , and director & Chief Executive Officer David Tapolczay .

Conduit Pharmaceuticals Inc (CDT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Conduit Pharmaceuticals Inc (CDT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Conduit Pharmaceuticals Inc (CDT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Conduit Pharmaceuticals Inc (CDT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Conduit Pharmaceuticals Inc Insider Transactions

No Available Data

Andrew Regan Mailing Address

Above is the net worth, insider trading, and ownership report for Andrew Regan. You might contact Andrew Regan via mailing address: Le Manoir De Lurin, Saint Barthelemy Z0 97133.

Discussions on Andrew Regan

No discussions yet.